Table 2.
COVID-19 vaccines within WHO emergency use listing (EUL) and prequalification (PQ) evaluation process
| Platform | Name of vaccine | Manufacturer/WHO EUL holder | NRA of record |
|---|---|---|---|
| mNRA | BNT162b2/COMIRNATY | Pfizer–BioNTech | USFDA, EMA |
| mRNA-1273/Spikevax | Moderna Biotech | USFDA, EMA | |
| CVnCoV/CV07050101 | CureVac N.V. | EMA | |
| Adenoviral vector | AZD1222/Vaxzevria | Oxford University, AstraZeneca | EMA, MFDS KOREA, Japan, Australia TGA |
| Ad26.COV2.S/Janssen COVID-19 vaccine | Janssen-Cilag International NV | EMA | |
| Gam-COVID-Vac/Sputnik V | Gamaleya Research Institute of Epidemiology and Microbiology | Russian NRA | |
| Covishield | Serum Institute of India Pvt. Ltd. | DCGI | |
| Ad5-nCoV/Convidecia | CanSino Biologics | NMPA | |
| Inactivated | SARS-CoV-2 vaccine (vero cell), inactivated | Sinopharm/Beijing Institute of Biological Products | NMPA |
| COVID-19 vaccine (vero cell), inactivated | Sinovac Life Sciences | NMPA | |
| SARS-CoV-2 vaccine, inactivated (vero cell)/COVAXIN | Bharat Biotech, India | DCGI | |
| Inactivated SARS-CoV-2 vaccine (vero cell) | Sinopharm/WIBP | NMPA | |
| SARS-CoV-2 vaccine, inactivated (vero cell) | IMBCAMS, China | NMPA | |
| Protein | NVX-CoV2373/Covovax | Novavax | EMA |
| CoV2 preS dTM-AS03 vaccine | SANOFI | EMA | |
| SCB-2019 | Clover Biopharmaceuticals | NMPA | |
| Recombinant novel coronavirus vaccine (CHO Cell) | Zhifei Longcom, China | NMPA | |
| Soberana 02 | BioCubaFarma – Cuba | CECMED | |
| Peptide | EpiVacCorona | State Research Center of Virology and Biotechnology | Russian NRA |
NRA, National Regulatory Authority; USFDA, The United States Food and Drug Administration; EMA, European Medicines Agency; MFDS, Ministry of Food and Drug Safety; TGA, Therapeutic Goods Administration; DCGI, Drugs Controller General of India; NMPA, National Medical Products Administration of CHINA; CECMED, Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos, Cuba.